Cutaneous Melanoma ARTISTRY-6, Cohorts 3 & 4
Dosing: Nemvaleukin (LFIV) Monotherapy and Combination with Pembrolizumab
Anticipated Program Milestone:
Preliminary data readout for cohort 3 (monotherapy) expected in 1H2025 and for cohort 4 (combination therapy) in 2H 2025 (subject to patient enrollment)